November 18th, 2026 | 05:36 CET
A three-way look: What Allianz shareholders, BioNTech investors and HPQ Silicon speculators should know now!
Created and published on behalf of HPQ Silicon
Allianz is delivering impressive record results. Vaccine specialist BioNTech continues to advance its oncology pipeline. Canadian small-cap HPQ Silicon may once again be on the verge of a promising technical breakout, as it was several years ago. Whether it is fundamental strength in the insurance sector, billion-dollar research bets in biotech and cancer drugs or speculative technology potential in batteries and energy storage, the following sections examine the opportunities, risks and financial data of these three very different stocks, providing investors with valuable guidance for their next strategic portfolio decisions.
time to read: 5 minutes | Author: Matthias Schomber
ISIN: HPQ Silicon Inc | CA40444L1031 , DE0008404005 , BIONTECH SE SPON. ADRS 1 | US09075V1026
Table of contents:
Author
Matthias Schomber
Raised in Giessen, Hesse, Matthias Schomber discovered his passion for the financial markets as early as the 1990s—at a time when stock trading was still largely the domain of true, die-hard traders. After completing his banking apprenticeship, he worked for a private bank there and witnessed the rise and fall of the Neuer Markt firsthand on the trading floor of the Frankfurt Stock Exchange, drawing lessons from the experience that continue to shape his thinking as a trader, author, and trading system developer to this day.
Tag cloud
Shares cloud
BioNTech: Range-bound technicals and million-dollar bets in oncology
Mainz-based biotechnology pioneer BioNTech has been trading within a relatively moderate technical range for months and is looking for clear catalysts beyond its waning coronavirus business to trigger a breakout. The share is trading around EUR 77.70 on Xetra and is fighting hard to avoid a sustained break below the key support zone in the EUR 72 – 73 range. Investors are transfixed by the painful memories of previous highs of just over EUR 397, while management is pushing ahead with the transformation into an oncology-focused group through moves worth billions.
On the operational side, the books show third-quarter revenue of EUR 1.29 billion and a quarterly profit of EUR 184.5 million, while a net loss of EUR 1.17 billion is nevertheless recorded after nine months. To accelerate its clinical pipeline and future regulatory approvals, BioNTech recently secured a valuable Priority Review Voucher from Scholar Rock for USD 205 million in cash. At the same time, the company has solid cash reserves and securities of around EUR 16.2 billion, comfortably covering the strategic acquisition despite operating losses over the course of the year.
The investment strategy for BioNTech remains a bet on a scientific breakthrough in cancer medicine, as approved cancer products have yet to prove themselves commercially. Downside protection comes from the substantial cash reserves, as mentioned above. Despite ambitious analyst price targets, some of which put the company's fair value well above EUR 100, shareholders bear the full clinical trial risk and must continue to brace themselves for high volatility. Investing in the Mainz-based biotech pioneer means backing long-term innovation, but it requires patience and, quite possibly, nerves of steel.
A sustained breakout above the EUR 100 mark should support a rise towards EUR 120. Beyond that, there is considerable room up to the EUR 150 to EUR 180 range. On the downside, however, the share should not fall below the area around EUR 72 again, as this would otherwise cloud the technical picture.
From biotechnology, the focus shifts directly to the European insurance sector, where Allianz stands like a rock in a storm, supported by a superb upward chart trend.
Allianz: Record profits and dividends provide a boost
Munich-based insurance group Allianz is riding a historic wave of success and setting new record highs on the stock market. Supported by a strong run in asset management and robust property and casualty divisions, the share climbed to EUR 479 in November 2026. The industry leader is impressively demonstrating that it can generate excellent returns for its shareholders even in geopolitically turbulent times.
In the third quarter, Allianz increased its group operating profit by 6% to EUR 4.7 billion, impressively exceeding average analyst estimates of around EUR 4.3 billion. After nine months, record operating profit totals a strong EUR 14.1 billion, prompting management to raise the upper end of its full-year guidance to EUR 18.6 billion. Although natural catastrophes such as hailstorms in Europe resulted in net claims of EUR 1.1 billion in the property and casualty business, strong net inflows into the fund businesses at Pimco and AllianzGI, along with a sharp rise in asset management profits, appear to have more than offset these operational burdens.
With an excellent Solvency II ratio of 219% and the EUR 2.5 billion share buyback programme completed in September, Allianz offers a first-class financial foundation for continuous and attractive distributions. Even with valuations now elevated and expert price targets averaging over EUR 450 and reaching peaks of up to EUR 684, the stock currently remains a stable anchor in many portfolios. Investors get solid fundamentals coupled with sustainable dividend strength, although increasing price competition in the corporate client business will need to be closely monitored in future.
From a technical perspective, however, the share should not fall below the EUR 400 mark again, as it would then be below both the 50-day and 200-day SMAs and would have shifted into a downtrend.
Those who shift their focus from the insurance giant to the future markets of the cleantech sector may well come across an intriguing Canadian small-cap stock that could now be worth considering at its current share price.
HPQ Silicon: Is the greentech hidden gem now on the verge of a major trend reversal?
HPQ Silicon shares have been relatively quiet on the stock market in recent months, but could now gain noticeable momentum thanks to fresh operational milestones and strategic partnerships. From a technical perspective, the share is currently at CAD 0.095 and is fighting to achieve a sustained breakout above the descending trend channel in place since spring 2026. A sustained jump above the important resistance zone at CAD 0.12 to CAD 0.13 could provide the starting signal for a significant upward move.
As a technology developer, the company focuses on three pioneering pillars: silicon-based anode materials for batteries in partnership with Novacium, highly efficient reactors for fumed silica with PyroGenesis, and autonomous green hydrogen systems. Recent news from October 2026 underscores the operational momentum, including the approval of around EUR 1.0 million in funding for the METAGENE™ hydrogen project under the stringent RAPID programme. However, RAPID funding goes to the consortium of Novacium, Axel'One, and AD-VENTA, not directly to HPQ, though HPQ holds a 36.8% stake in Novacium.
On the downside, historical technical support from 2020 in the CAD 0.08 to CAD 0.09 range offers a potentially reliable floor, while recently increased trading volume is likely to signal growing interest from buyers.

Should the technical breakout above the key resistance zone at CAD 0.12 or CAD 0.13 succeed, price targets around CAD 0.20 and the previous year's high of CAD 0.24 to CAD 0.25 will quickly come into focus for investors. Historically, this setup strongly resembles 2020, when a comparable price level marked the start of a spectacular surge to over CAD 1.60.
For risk-tolerant investors, HPQ Silicon offers a highly interesting asymmetry between downside risk that is currently manageable from a technical perspective and considerable speculative potential in pioneering rechargeable battery materials research.
Conclusion
BioNTech remains an exciting but risky bet on a clinical breakthrough in oncology that demands patience and strong nerves. Allianz impresses as a fundamentally solid rock in the DAX with record results, excellent capitalisation and a strong dividend yield. HPQ Silicon is a speculative cleantech hidden gem that could unleash explosive potential for a manifold increase if it achieves a sustained breakout above technical resistance levels.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.



